JPMorgan Chase & Co. Raises Cabot (NYSE:CBT) Price Target to $78.00

Key Points

• JPMorgan raised Cabot’s price target from $70 to $78 but maintained an “underweight” rating, implying 9.44% downside from the prior close.
• Analyst sentiment remains cautious: Cabot has a consensus “Hold” rating and an average price target of $89, with ratings spanning Buy, Hold and Sell.
• Cabot reported quarterly EPS of $1.67, narrowly exceeding estimates, while revenue of $982 million surpassed expectations and increased 6.4% year over year.

Cabot (NYSE:CBT - Get Free Report) had its price target lifted by JPMorgan Chase & Co. from $70.00 to $78.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an "underweight" rating on the specialty chemicals company's stock. JPMorgan Chase & Co.'s price objective suggests a potential downside of 9.44% from the stock's previous close.

Other equities analysts have also issued research reports about the company. Mizuho increased their target price on Cabot from $80.00 to $90.00 and gave the company a "neutral" rating in a report on Thursday, June 25th. UBS Group lowered their price objective on Cabot from $97.00 to $92.00 and set a "neutral" rating for the company in a research report on Wednesday. Truist Financial set a $100.00 price objective on Cabot in a report on Wednesday. Weiss Ratings reissued a "hold (c)" rating on shares of Cabot in a research report on Tuesday, May 26th. Finally, Wall Street Zen downgraded Cabot from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $89.00.

Cabot Stock Down 1.6%

Shares of CBT stock traded down $1.42 during trading hours on Friday, reaching $86.13. 69,311 shares of the stock were exchanged, compared to its average volume of 480,132. The business's fifty day moving average is $87.92 and its two-hundred day moving average is $79.82. The firm has a market capitalization of $4.45 billion, a P/E ratio of 24.34, a P/E/G ratio of 11.03 and a beta of 0.84. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 0.96.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.66 by $0.01. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The company had revenue of $982.00 million during the quarter, compared to analysts' expectations of $943.16 million. During the same quarter in the previous year, the business posted $1.90 EPS. The firm's revenue was up 6.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. As a group, research analysts expect that Cabot will post 6.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Cabot

A number of institutional investors have recently modified their holdings of the business. Norges Bank purchased a new position in shares of Cabot in the 4th quarter valued at approximately $49,662,000. Bank of New York Mellon Corp purchased a new stake in shares of Cabot during the second quarter worth approximately $57,445,000. AQR Capital Management LLC lifted its holdings in shares of Cabot by 123.0% during the second quarter. AQR Capital Management LLC now owns 867,946 shares of the specialty chemicals company's stock worth $65,096,000 after purchasing an additional 478,702 shares during the period. UBS Group AG lifted its holdings in shares of Cabot by 186.7% during the third quarter. UBS Group AG now owns 593,510 shares of the specialty chemicals company's stock worth $45,136,000 after purchasing an additional 386,514 shares during the period. Finally, Pacer Advisors Inc. grew its position in Cabot by 3,165.7% in the 4th quarter. Pacer Advisors Inc. now owns 229,252 shares of the specialty chemicals company's stock valued at $15,195,000 after buying an additional 222,232 shares during the last quarter. 93.18% of the stock is owned by institutional investors and hedge funds.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source